"Given the near-term commercial status of our dermal injector development and the nature of the discussions underway, we remain confident we will secure a revenue-generating, commercialization partnership for this asset next year," president and CEO, Lee Buckler, said in a statement.

In addition, he said the company is currently engaged in a number of early-stage partnership and collaboration discussions for each of its cell therapy programs.

“While we have already commenced planning preparation for our next-phase clinical trials, these discussions may influence how we prioritize and finance these studies,” he added.